List of AI healthcare startups in 2026: 11 names and where they fit
A list of AI healthcare startups grouped by job, from AI scribes and clinical search to imaging triage and drug discovery, with the evidence behind each.

If you want a list of AI healthcare startups that actually matter, start with the companies doctors already use: Abridge, Ambience and Suki for clinical notes, OpenEvidence for medical answers, Aidoc and Viz.ai for scan triage, and Insilico Medicine and Isomorphic Labs for drug discovery. They're not all equally proven. In my view, the documentation and imaging companies have the strongest evidence behind them, while drug discovery is still a long bet.
Below, I've grouped eleven names by the job they do, then looked at where the evidence is thin and what it means if you're a patient, a clinician or someone buying software for a hospital.
The background: why AI startups in healthcare took off
Healthcare has two problems that suit current AI well. There's a mountain of text (notes, letters, guidelines, insurance paperwork), and there's a shortage of people with time to read and write it. Large language models are good at text. So it's no surprise that the first wave of AI startups in healthcare to win real contracts went after paperwork, not diagnosis.
The money followed. Digital health companies raised $7.4 billion in the first half of the year, and nearly half of that went into 20 megadeals of $100 million or more. OpenEvidence raised $250 million in one of them; Aidoc took its second $150 million round in less than a year.
Imaging is the older strand. Radiology software has been using machine learning for a decade, and it runs through a regulator that's used to it. The FDA has authorized more than 1,600 AI-enabled medical devices, a count that runs to September 2026. That list matters because a note-taking tool usually doesn't need FDA clearance, while software that flags a stroke on a CT scan does.
Drug discovery is the third strand, and the slowest. A new medicine takes years to move through trials, so a startup founded five years ago is only now finding out whether its AI picked good targets.
A list of AI healthcare startups worth knowing
I've kept this to companies that are still private and that I could verify from their own sites. Big public firms (Tempus, Microsoft's Nuance) are left out on purpose, since they aren't startups any more.
| Startup | Area | Main users | One detail worth knowing |
|---|---|---|---|
| Abridge | Clinical documentation | Health systems | Says it's trusted by 300+ health systems |
| Ambience Healthcare | Documentation and coding | Health systems | Pitches coding accuracy and return on investment |
| Suki | Ambient assistant | Clinicians, health tech partners | Covers 100+ specialties on desktop and mobile |
| OpenEvidence | Clinical search | Doctors | Free for clinicians, funded by ads |
| Hippocratic AI | Voice agents | Providers, payers | Claims 323M+ patient interactions |
| Hyro | Patient calls and messages | Call centres | Handles scheduling, refills and bills |
| Aidoc | Imaging triage | Radiology teams | Used in 1,600+ medical centres |
| Viz.ai | Care coordination | Stroke and cardiac teams | 50+ FDA-cleared algorithms |
| PathAI | Digital pathology | Labs, pharma | Sells the AISight image platform |
| Insilico Medicine | Drug discovery | Pharma partners | Lead program targets lung fibrosis |
| Isomorphic Labs | Drug design | Its own pipeline | Lead programs heading toward the clinic |
Documentation: Abridge, Ambience and Suki
These three listen to a visit and draft the note. Abridge has pushed furthest into the rest of the day: its site now talks about preparing the note before the visit, surfacing care gaps during it, and handling coding and orders afterwards. Ambience leans on money, quoting a 3x return and 95% coding compliance verified by the AAPC (those are its own figures, so weigh them that way). Suki sells both a clinician app and a toolkit that other health tech firms can build into their products. If you want more on the market leader, our Abridge AI review goes through it in detail.
Clinical answers: OpenEvidence
OpenEvidence is a search engine for doctors that answers with citations from medical journals. It's free to verified clinicians and paid for by advertising, which is clever and slightly uncomfortable at the same time. It's an official AI partner of the New England Journal of Medicine, and the company says more than 40% of US physicians use it daily. Its valuation doubled to $12 billion with that $250 million round.
Patient-facing agents: Hippocratic AI and Hyro
Hippocratic AI builds voice agents that call patients for things like follow-ups and reminders. It lists "Zero" incidents of harm since inception, and its newest model family, Polaris 6, is priced in credits per hour of conversation. Hyro does the front desk version: rescheduling, prescription refills and bill payments by phone, chat and text. Our comparison of Hyro with outsourced revenue cycle teams covers the trade-offs.
Imaging and pathology: Aidoc, Viz.ai and PathAI
This is where the FDA list does most of its work. Viz.ai says its platform runs on more than 50 FDA-cleared algorithms across CT scans, EKGs and echocardiograms. Aidoc quotes a 34% cut in door-to-puncture time for stroke patients, roughly 38 minutes.
PathAI does the same kind of thing for microscope slides, and a lot of its business is with drug companies looking for biomarkers.
Drug discovery: Insilico Medicine and Isomorphic Labs
Insilico Medicine has the longer public track record. Its pipeline lists more than 20 programs, several already licensed to partners such as Exelixis and Menarini, with idiopathic pulmonary fibrosis at the top. Isomorphic Labs, the Alphabet spin-out built on the protein structure work behind AlphaFold, is younger; it says its lead internal programs are "now advancing towards the clinic". I'd treat both as research bets rather than products you can judge today.
Benefits and limitations
The best evidence so far is for scribes, and it's more modest than the marketing. A randomized trial at UCLA Health, published in NEJM AI, put 238 physicians across 14 specialties on Microsoft DAX, Nabla or their usual routine for two months. Nabla users cut time per note by about 41 seconds, from 4 minutes 30 to 3 minutes 49, against 18 seconds for the control group. DAX's drop wasn't statistically significant. Both tools improved burnout scores by roughly 7%.
Forty-one seconds sounds tiny. Multiply it by twenty patients a day, though, and it's about fourteen minutes back, which is a coffee break most doctors don't currently get.
The same trial found the notes "occasionally" contained clinically significant errors, mostly omissions and wrong pronouns, and one mild patient safety event was reported. That's the limitation I'd keep in mind across this whole list. An AI scribe is a bit like a fast junior colleague: helpful, but you'd still read what it wrote before signing it.
Other limits are less obvious:
- Most headline numbers (adoption rates, return on investment, "zero harm") come from the companies themselves.
- FDA clearance covers a narrow intended use, not general accuracy.
- Ad-funded clinical tools raise fair questions about who pays and what gets shown.
- Drug discovery claims can't be judged until late-stage trials report.
Practical takeaways for patients, clinicians and buyers
If you're a patient, you'll probably meet these tools without being told much. Your doctor may ask to record the visit for an AI scribe; fewer than 10% of patients declined in the UCLA trial. You can say no. You can also ask to see the note afterwards, which I think is a good habit anyway.
If you're a clinician, the scribes seem worth trying, but budget your review time honestly. Checking a draft still takes attention. OpenEvidence is free, so there's little cost to testing its answers against what you already know.
Buying for a hospital is harder. I'd ask every vendor three plain questions: which parts need FDA clearance and have it, what independent studies exist, and what happens to your patients' data. If you're building skills on the clinical side, our guide to AI in healthcare certificates is a reasonable place to start. And if you're thinking about the business side, our piece on mental health startup revenue models explains why most of these firms sell to institutions, not consumers.
Next for AI startups in healthcare
Two shifts look likely. First, the general labs are moving in: OpenAI and Anthropic both now have health offerings, which puts pressure on any startup whose only edge is a good model. Rock Health's researchers made a similar point in their mid-year report, arguing that buyers now ask "Who has something AI alone can't provide?"
Second, the scribes are turning into something bigger. Abridge and Ambience both now describe products that also handle coding, orders and billing. I suspect that's where the real fights happen next, because that's where hospitals spend money.
For drug discovery, the next few years will tell us whether AI-designed molecules work better in people, or only arrive faster. My guess is "a bit of both", and it'll vary by disease. For a wider view beyond medicine, see our list of the hottest AI startups.
FAQ
Which AI healthcare startup is the most valuable?
Among the names here, OpenEvidence has the clearest public figure: its Series D valued it at $12 billion. Private valuations change with each round, though, and they say more about investor appetite than about how well a tool works in clinics.
Are AI healthcare tools approved by the FDA?
Some are. The FDA has authorized more than 1,600 AI-enabled medical devices, mostly in imaging. Tools that diagnose or triage, like Viz.ai's stroke algorithms, need clearance. Most AI scribes and admin tools don't count as medical devices, so they usually aren't reviewed by the FDA at all.
Can patients use these AI tools directly?
Mostly not. Nearly every startup on this list sells to hospitals, insurers or drug companies rather than to individuals. OpenEvidence is aimed at verified clinicians. Patients usually meet these tools indirectly, through a scribe in the exam room, a voice agent calling with reminders or software reading their scan. If a clinic uses one, it's reasonable to ask what the tool does and who checks its output.
Will AI healthcare startups replace doctors?
I doubt it, at least not soon. The best-tested tools save minutes on paperwork and still make errors that a clinician has to catch. Imaging AI flags scans for a radiologist to read; it doesn't sign the report. The likelier change is fewer administrative jobs and more checking work for doctors.

